← Back to Clinical Trials
Recruiting Phase 2, Phase 3 NCT05166343

NCT05166343 POHCA Resuscitation: Evaluation of IM Epinephrine

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05166343
Status Recruiting
Phase Phase 2, Phase 3
Sponsor London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Condition Pediatric Out-of-Hospital Cardiac Arrest
Study Type INTERVENTIONAL
Enrollment 284 participants
Start Date 2024-01-08
Primary Completion 2028-01

Eligibility & Interventions

Sex All sexes
Min Age 1 Day
Max Age 17 Years
Study Type INTERVENTIONAL
Interventions
Epinephrine Injection

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.

This trial targets 284 participants in total. It began in 2024-01-08 with a primary completion date of 2028-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is a pragmatic, two-arm, open-label, prospective stepped-wedge cluster quasi randomized control trial (SW-CRCT) looking to evaluate early intramuscular (IM) epinephrine in the management of pediatric out-of-hospital cardiac arrest (POHCA).

Eligibility Criteria

Inclusion Criteria: * Children aged 1 day to and including 17 years experiencing an out-of-hospital cardiac arrest (OHCA) * Must be receiving at least 1 minute of CPR by trained first responders (police, fire, or paramedic services) Exclusion Criteria: \- Children who experience OHCA due to an obvious traumatic event.

Contact & Investigator

Central Contact

Maysaa Assaf

✉ maysaa.assaf@lhsc.on.ca

📞 519-685-8500

Principal Investigator

Janice Tijssen, MD MSc

PRINCIPAL INVESTIGATOR

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Frequently Asked Questions

Who can join the NCT05166343 clinical trial?

This trial is open to participants of all sexes, aged 1 Day or older, up to 17 Years, studying Pediatric Out-of-Hospital Cardiac Arrest. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT05166343 trial and what does that mean for participants?

Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.

Is NCT05166343 currently recruiting?

Yes, NCT05166343 is actively recruiting participants. Contact the research team at maysaa.assaf@lhsc.on.ca for enrollment information.

Where is the NCT05166343 trial being conducted?

This trial is being conducted at London, Canada.

Who is sponsoring the NCT05166343 clinical trial?

NCT05166343 is sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. The principal investigator is Janice Tijssen, MD MSc at London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. The trial plans to enroll 284 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology